Literature DB >> 3476127

Human immunodeficiency virus: the eighth gene.

F Wong-Staal, P K Chanda, J Ghrayeb.   

Abstract

Human T-lymphotropic virus type III (HTLV-III/LAV) has been shown to contain at least four extra genes in addition to the three essential genes (gag, pol, env) for replication of most retroviruses. These genes are expressed by complex splicing mechanisms and utilization of overlapping reading frames. We now demonstrate that there is an eighth gene which encodes a protein which is immunogenic and recognized by sera of some HTLV-III seropositive people. The gene is highly conserved among all known HTLV-III isolates and exhibits a polymorphism at the 3' end which distinguishes several molecular clones of the HTLV-IIIB cell line from those of other HTLV-III/LAV isolates. The function of this gene is unknown.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3476127     DOI： 10.1089/aid.1987.3.33

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


  45 in total

1.  Integrase-lexA fusion proteins incorporated into human immunodeficiency virus type 1 that contains a catalytically inactive integrase gene are functional to mediate integration.

Authors:  M L Holmes-Son; S A Chow
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants.

Authors:  P Westervelt; T Henkel; D B Trowbridge; J Orenstein; J Heuser; H E Gendelman; L Ratner
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

3.  Viral protein R of human immunodeficiency virus types 1 and 2 is dispensable for replication and cytopathogenicity in lymphoid cells.

Authors:  D Dedera; W Hu; N Vander Heyden; L Ratner
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

4.  HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, a substrate recognition subunit of a cullin 4A-ring E3 ubiquitin ligase for proteasome-dependent degradation.

Authors:  Jinwoo Ahn; Thomas Vu; Zach Novince; Jennifer Guerrero-Santoro; Vesna Rapic-Otrin; Angela M Gronenborn
Journal:  J Biol Chem       Date:  2010-09-24       Impact factor: 5.157

Review 5.  HIV-1 Vpr: mechanisms of G2 arrest and apoptosis.

Authors:  Joshua L Andersen; Erwann Le Rouzic; Vicente Planelles
Journal:  Exp Mol Pathol       Date:  2008-04-25       Impact factor: 3.362

6.  Genetic variability between isolates of human immunodeficiency virus (HIV) type 2 is comparable to the variability among HIV type 1.

Authors:  J F Zagury; G Franchini; M Reitz; E Collalti; B Starcich; L Hall; K Fargnoli; L Jagodzinski; H G Guo; F Laure
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

7.  A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles.

Authors:  Y L Lu; R P Bennett; J W Wills; R Gorelick; L Ratner
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  A domain of human immunodeficiency virus type 1 Vpr containing repeated H(S/F)RIG amino acid motifs causes cell growth arrest and structural defects.

Authors:  I G Macreadie; L A Castelli; D R Hewish; A Kirkpatrick; A C Ward; A A Azad
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

Review 9.  Site-specific integration of retroviral DNA in human cells using fusion proteins consisting of human immunodeficiency virus type 1 integrase and the designed polydactyl zinc-finger protein E2C.

Authors:  Kunkai Su; Dan Wang; Jian Ye; Yun C Kim; Samson A Chow
Journal:  Methods       Date:  2009-01-30       Impact factor: 3.608

10.  HIV-1 Vpr Inhibits Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Inducing MicroRNA miR-942-5p and Activating NF-κB Signaling.

Authors:  Qin Yan; Chenyou Shen; Jie Qin; Wan Li; Minmin Hu; Hongmei Lu; Di Qin; Jianzhong Zhu; Shou-Jiang Gao; Chun Lu
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.